RESUMEN
BACKGROUND: Passiflora incarnata is widely used as an anxiolytic and sedative due to its putative GABAergic properties. Passiflora incarnata L. methanolic extract (PI-ME) was evaluated in an animal model of streptozotocin-induced diabetic neuropathic allodynia and vulvodynia in rats along with antinociceptive, anxiolytic and sedative activities in mice in order to examine possible underlying mechanisms. METHODS: PI-ME was tested preliminary for qualitative phytochemical analysis and then quantitatively by proximate and GC-MS analysis. The antinociceptive property was evaluated using the abdominal constriction assay and hot plate test. The anxiolytic activity was performed in a stair case model and sedative activity in an open field test. The antagonistic activities were evaluated using naloxone and/or pentylenetetrazole (PTZ). PI-ME was evaluated for prospective anti-allodynic and anti-vulvodynic properties in a rat model of streptozotocin induced neuropathic pain using the static and dynamic testing paradigms of mechanical allodynia and vulvodynia. RESULTS: GC-MS analysis revealed that PI-ME contained predominant quantities of oleamide (9-octadecenamide), palmitic acid (hexadecanoic acid) and 3-hydroxy-dodecanoic acid, among other active constituents. In the abdominal constriction assay and hot plate test, PI-ME produced dose dependant, naloxone and pentylenetetrazole reversible antinociception suggesting an involvement of opioidergic and GABAergic mechanisms. In the stair case test, PI-ME at 200 mg/kg increased the number of steps climbed while at 600 mg/kg a significant decrease was observed. The rearing incidence was diminished by PI-ME at all tested doses and in the open field test, PI-ME decreased locomotor activity to an extent that was analagous to diazepam. The effects of PI-ME were antagonized by PTZ in both the staircase and open field tests implicating GABAergic mechanisms in its anxiolytic and sedative activities. In the streptozotocin-induced neuropathic nociceptive model, PI-ME (200 and 300 mg/kg) exhibited static and dynamic anti-allodynic effects exemplified by an increase in paw withdrawal threshold and paw withdrawal latency. PI-ME relieved only the dynamic component of vulvodynia by increasing flinching response latency. CONCLUSIONS: These findings suggest that Passiflora incarnata might be useful for treating neuropathic pain. The antinociceptive and behavioural findings inferring that its activity may stem from underlying opioidergic and GABAergic mechanisms though a potential oleamide-sourced cannabimimetic involvement is also discussed.
Asunto(s)
Analgésicos/uso terapéutico , Ansiolíticos/uso terapéutico , Neuropatías Diabéticas/tratamiento farmacológico , Hiperalgesia/tratamiento farmacológico , Hipnóticos y Sedantes/uso terapéutico , Passiflora/química , Vulvodinia/tratamiento farmacológico , Dolor Abdominal/tratamiento farmacológico , Analgésicos/análisis , Analgésicos/farmacología , Analgésicos Opioides , Animales , Ansiolíticos/análisis , Ansiolíticos/farmacología , Ansiedad/tratamiento farmacológico , Conducta Animal/efectos de los fármacos , Diabetes Mellitus Experimental/complicaciones , Diabetes Mellitus Experimental/patología , Neuropatías Diabéticas/patología , Ácidos Grasos/análisis , Ácidos Grasos/farmacología , Ácidos Grasos/uso terapéutico , Femenino , Agonistas del GABA/análisis , Agonistas del GABA/farmacología , Agonistas del GABA/uso terapéutico , Calor , Hipnóticos y Sedantes/análisis , Hipnóticos y Sedantes/farmacología , Masculino , Ratones Endogámicos BALB C , Neuralgia/tratamiento farmacológico , Fitoterapia , Extractos Vegetales/química , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéuticoRESUMEN
Undertreatment of pain (oligoanalgesia) in the emergency department is common, and it negatively impacts patient care. Both failure of appropriate pain assessment and the potential for unsafe analgesic use contribute to the problem. As a result, achieving satisfactory analgesia while minimizing side effects remains particularly challenging for emergency physicians, both in the emergency department and after a patient is discharged. Improvements in rapid pain assessment and in evaluation of noncommunicative populations may result in a better estimation of which patients require analgesia and how much pain is present. New formulations of available treatments, such as rapidly absorbed, topical, or intranasal nonsteroidal anti-inflammatory drug formulations or intranasal opioids, may provide effective analgesia with an improved risk-benefit profile. Other pharmacological therapies have been shown to be effective for certain pain modalities, such as the use of antidepressants for musculoskeletal pain, γ-aminobutyric acid agonists for neuropathic and postsurgical pain, antipsychotics for headache, and topical capsaicin for neuropathic pain. Nonpharmacological methods of pain control include the use of electrical stimulation, relaxation therapies, psychosocial/manipulative therapies, and acupuncture. Tailoring of available treatment options to specific pain modalities, as well as improvements in pain assessment, treatment options, and formulations, may improve pain control in the emergency department setting and beyond.
Asunto(s)
Analgésicos Opioides/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Servicio de Urgencia en Hospital , Manejo del Dolor/métodos , Terapia por Acupuntura , Analgésicos Opioides/administración & dosificación , Analgésicos Opioides/efectos adversos , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/efectos adversos , Antidepresivos/uso terapéutico , Antipsicóticos/uso terapéutico , Capsaicina/uso terapéutico , Inhibidores de la Ciclooxigenasa/uso terapéutico , Quimioterapia Combinada , Agonistas del GABA/uso terapéutico , Humanos , Manejo del Dolor/efectos adversos , Dimensión del Dolor , Estimulación Eléctrica Transcutánea del NervioRESUMEN
Neurotransmitter imbalance is an inevitable outcome in cerebral ischemia that leads to neuronal death. In the present study, we evaluated the effects of piroxicam, a nonsteroidal anti-inflammatory drug (NSAID), on extracellular brain glutamate and γ-aminobutyric acid (GABA) release, survival time, and neuronal cell death. Transient focal cerebral ischemia in male Charles Foster rat led to neuronal infarction and compromised intrinsic antioxidant status. Thirty-minute preadministration of piroxicam (10 mg/kg b.w.) showed a significant (P < 0.01) reduction in cerebral infarct volume and potentiation of the intrinsic antioxidant status. High-performance liquid chromatography of brain cortex and striatum revealed changes in extracellular concentrations of neurotransmitters which were found to be 0.519 ± 0.44 pmole/mg (GABA); 1.18 ± 0.28 pmole/mg (glutamate), and 0.63 ± 0.21 pmole/mg (serotonin), respectively. Hydroxyl radical (·OH) adduct of salicylate in the frontal cortex and striatum in control, untreated, and treated groups was found to be 0.261 ± 0.06, 0.68 ± 0.52, and 0.401 ± 0.68 pmole/mg, respectively. After stroke, the extracellular level of glutamate in rat brain increases continuously as compared to that of control group. However, piroxicam administration in stroke rat significantly reduced (P < 0.05) elevated extracellular cerebral glutamate. This indicates that piroxicam attenuates extracellular glutamate release and also reduces neuronal cell death due to reduction in oxidative stress in cerebral ischemia. Our results also indicate a consequent increase of extracellular GABA in brain regions administered with piroxicam, which hints that piroxicam alleviates glutamate excitotoxicity possibly by GABA agonism.
Asunto(s)
Agonistas del GABA/farmacología , Ácido Glutámico/fisiología , Infarto de la Arteria Cerebral Media/tratamiento farmacológico , Fármacos Neuroprotectores/farmacología , Piroxicam/farmacología , Animales , Antiinflamatorios no Esteroideos/farmacología , Antiinflamatorios no Esteroideos/uso terapéutico , Catalasa/metabolismo , Células Cultivadas , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/patología , Evaluación Preclínica de Medicamentos , Agonistas del GABA/uso terapéutico , Infarto de la Arteria Cerebral Media/patología , Masculino , Fármacos Neuroprotectores/uso terapéutico , Piroxicam/uso terapéutico , Ratas , Superóxido Dismutasa/metabolismo , Superóxidos/metabolismo , Ácido gamma-Aminobutírico/metabolismoRESUMEN
The mode of action of the anxiolytic medicinal plant Souroubea sympetala was investigated to test the hypothesis that extracts and the active principle act at the pharmacologically important GABAA-benzodiazepine (GABAA-BZD) receptor. Leaf extracts prepared by ethyl acetate extraction or supercritical extraction, previously determined to have 5.54 mg/g and 6.78 mg/g of the active principle, betulinic acid, respectively, reduced behavioural parameters associated with anxiety in a rat model. When animals were pretreated with the GABAA-BZD receptor antagonist flumazenil, followed by the plant extracts, or a more soluble derivative of the active principle, the methyl ester of betulinic acid (MeBA), flumazenil eliminated the anxiety-reducing effect of plant extracts and MeBA, demonstrating that S. sympetala acts via an agonist action on the GABAA-BZD receptor. An in vitro GABAA-BZD competitive receptor binding assay also demonstrated that S. sympetala extracts have an affinity for the GABAA-BZD receptor, with an EC50 value of 123 µg/mL (EtOAc leaf extract) and 154 µg/mL (supercritical CO2 extract). These experiments indicate that S. sympetala acts at the GABAA-BZD receptor to elicit anxiolysis.
Asunto(s)
Ansiolíticos/uso terapéutico , Ansiedad/tratamiento farmacológico , Agonistas del GABA/uso terapéutico , Extractos Vegetales/uso terapéutico , Receptores de GABA-A/metabolismo , Triterpenos/uso terapéutico , Animales , Ansiolíticos/farmacología , Ansiedad/psicología , Flumazenil/farmacología , Agonistas del GABA/farmacología , Antagonistas del GABA/farmacología , Masculino , Fitoterapia , Corteza de la Planta/química , Extractos Vegetales/farmacología , Hojas de la Planta/química , Plantas Medicinales , Ratas Sprague-Dawley , Triterpenos/farmacologíaRESUMEN
BACKGROUND: Because chronic tinnitus is a condition that negatively impacts the quality of life of millions of people worldwide, a safe and effective treatment for tinnitus has been sought for millennia. However, effective treatments for tinnitus are greatly outnumbered by ineffective strategies, medications, devices, and surgeries that continue to be developed and promoted for the condition. PURPOSE: This article describes and critiques experimental, controversial, and potential treatments for chronic tinnitus. The purpose of this review is to provide information that should help patients and clinicians to select tinnitus treatment and management strategies most likely to be effective for each set of symptoms and circumstances. RESEARCH DESIGN: PubMed and MEDLINE databases (National Center for Biotechnology Information, U.S. National Library of Medicine) were searched for the term tinnitus in articles published from 1940 to 2012. Other historical documents and publications were also reviewed as needed for particular topics. STUDY SAMPLE: Studies included in this review were selected to represent a sampling of treatment methodologies that have been used for tinnitus. DATA COLLECTION AND ANALYSIS: Due to the heterogeneity of the studies reviewed, it was not appropriate to perform a meta-analysis. A selective review of the literature was conducted to summarize and critique published research results. RESULTS: Most invasive treatments for tinnitus should be avoided because (1) at best, there is scant evidence that any of these treatments is effective, and (2) the risk to patients for most invasive procedures is much greater than the risk posed by the tinnitus perception. Effective and noninvasive treatments for tinnitus include acoustic therapy (which includes hearing aids and other types of environmental sound enrichment); cognitive-behavioral therapy; psychological counseling; hypnosis; biofeedback; and relaxation training. Over-the-counter or prescription medications may be used as needed to facilitate sleep and to reduce anxiety, depression, or obsessive-compulsiveness. CONCLUSIONS: Patients and clinicians should be especially cautious when considering invasive (and potentially harmful) treatments for tinnitus, which is a non-life-threatening symptom. Unless well-designed clinical trials verify that a tinnitus therapy demonstrates effectiveness above and beyond the placebo effect, consumers should be wary of medications, devices, or procedures promoted as a "cure." Although a true cure for tinnitus has not yet been found, effective and noninvasive tinnitus management strategies are available now. If progress is made to medically (or genetically) treat sensorineural hearing loss in humans, this breakthrough should also help to simultaneously reduce the perception of tinnitus for many patients.
Asunto(s)
Estimulación Acústica/métodos , Terapia por Luz de Baja Intensidad , Otolaringología/métodos , Acúfeno/terapia , Estimulación Acústica/instrumentación , Ansiolíticos/uso terapéutico , Enfermedad Crónica , Terapia Cognitivo-Conductual/métodos , Bases de Datos Bibliográficas , Terapia por Estimulación Eléctrica/métodos , Agonistas del GABA/uso terapéutico , Terapia Genética , Audífonos , Pérdida Auditiva Sensorineural/rehabilitación , Medicina de Hierbas/métodos , Humanos , Magnetoterapia/métodos , Terapias Mente-Cuerpo/métodos , Otolaringología/tendencias , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Acúfeno/fisiopatología , Resultado del TratamientoRESUMEN
This paper demonstrates that in the treatment of psychiatric disorders, there are striking similarities between the mechanisms of psychoactive agents used in Traditional Chinese Medicine (TCM) and those of western psychopharmacology. While western researchers search for new treatments and novel mechanisms of action, investigators in Asia are analyzing traditional remedies in order to understand the mechanisms responsible for their effectiveness. A review of contemporary pharmacologic studies of agents used in TCM for psychiatric indications reveals that virtually all of the active principles of drug action established in 20th century psychopharmacology were encountered empirically in Chinese herbal medicine over the past 2000 years. Building bridges between these two traditions may thus be of benefit to both cultures. In addition to providing western patients with a wider selection of treatment options, the effort may help Asian clinicians and researchers avoid some of the errors that have troubled their western counterparts.
Asunto(s)
Medicina Tradicional China , Psicofarmacología , Psicotrópicos/uso terapéutico , Factor Neurotrófico Derivado del Encéfalo/fisiología , Dopamina/fisiología , Efedrina/uso terapéutico , Agonistas del GABA/uso terapéutico , Antagonistas del GABA/uso terapéutico , Humanos , Trastornos Mentales/tratamiento farmacológico , Inhibidores Selectivos de la Recaptación de Serotonina/farmacologíaRESUMEN
Temporal lobe epilepsy (TLE) is accompanied by an abnormal location of granule cells in the dentate gyrus. Using a rat model of complex febrile seizures, which are thought to be a precipitating insult of TLE later in life, we report that aberrant migration of neonatal-generated granule cells results in granule cell ectopia that persists into adulthood. Febrile seizures induced an upregulation of GABA(A) receptors (GABA(A)-Rs) in neonatally generated granule cells, and hyperactivation of excitatory GABA(A)-Rs caused a reversal in the direction of granule cell migration. This abnormal migration was prevented by RNAi-mediated knockdown of the Na(+)K(+)2Cl(-) co-transporter (NKCC1), which regulates the excitatory action of GABA. NKCC1 inhibition with bumetanide after febrile seizures rescued the granule cell ectopia, susceptibility to limbic seizures and development of epilepsy. Thus, this work identifies a previously unknown pathogenic role of excitatory GABA(A)-R signaling and highlights NKCC1 as a potential therapeutic target for preventing granule cell ectopia and the development of epilepsy after febrile seizures.
Asunto(s)
Epilepsia del Lóbulo Temporal/etiología , Proteínas del Tejido Nervioso/fisiología , Neuronas/patología , Receptores de GABA-A/fisiología , Convulsiones Febriles/fisiopatología , Ácido gamma-Aminobutírico/fisiología , Animales , Animales Lactantes , Encefalopatías/etiología , Encefalopatías/fisiopatología , Encefalopatías/prevención & control , Bumetanida/farmacología , Bumetanida/uso terapéutico , Linaje de la Célula , Movimiento Celular , Coristoma/etiología , Coristoma/fisiopatología , Coristoma/prevención & control , Giro Dentado , Susceptibilidad a Enfermedades , Epilepsia del Lóbulo Temporal/fisiopatología , Epilepsia del Lóbulo Temporal/prevención & control , Agonistas del GABA/uso terapéutico , Antagonistas del GABA/toxicidad , Genes Reporteros , Hipocampo/patología , Hipocampo/fisiopatología , Hipertermia Inducida/efectos adversos , Masculino , Proteínas del Tejido Nervioso/antagonistas & inhibidores , Proteínas del Tejido Nervioso/biosíntesis , Proteínas del Tejido Nervioso/genética , Neuronas/metabolismo , Especificidad de Órganos , Interferencia de ARN , Ratas , Ratas Sprague-Dawley , Receptores de GABA-A/biosíntesis , Receptores de GABA-A/genética , Convulsiones Febriles/complicaciones , Convulsiones Febriles/patología , Simportadores de Cloruro de Sodio-Potasio/genética , Simportadores de Cloruro de Sodio-Potasio/fisiología , Miembro 2 de la Familia de Transportadores de Soluto 12 , Regulación hacia ArribaRESUMEN
BACKGROUND: Our previous research with the GABA reuptake inhibitor tiagabine suggested the involvement GABA in the interoceptive effects of Δ9-THC. The aim of the present study was to determine the potential involvement of the GABA(B) receptor subtype by assessing the separate and combined effects of the GABA(B)-selective agonist baclofen and Δ9-THC using pharmacologically specific drug-discrimination procedures. METHODS: Eight cannabis users learned to discriminate 30 mg oral Δ9-THC from placebo and then received baclofen (25 and 50mg), Δ9-THC (5, 15 and 30 mg) and placebo, alone and in combination. Self-report, task performance and physiological measures were also collected. RESULTS: Δ9-THC functioned as a discriminative stimulus, produced subjective effects typically associated with cannabinoids (e.g., High, Stoned, Like Drug), elevated heart rate and impaired rate and accuracy on a psychomotor performance task. Baclofen alone (50 mg) substituted for the Δ9-THC discriminative stimulus, and both baclofen doses shifted the discriminative-stimulus effects of Δ9-THC leftward/upward. Similar results were observed on other cannabinoid-sensitive outcomes, although baclofen generally did not engender Δ9-THC-like subjective responses when administered alone. CONCLUSIONS: These results suggest that the GABA(B) receptor subtype is involved in the abuse-related effects of Δ9-THC, and that GABA(B) receptors were responsible, at least in part, for the effects of tiagabine-induced elevated GABA on cannabinoid-related behaviors in our previous study. Future research should test GABAergic compounds selective for other GABA receptor subtypes (i.e., GABA(A)) to determine the contribution of the different GABA receptors in the effects of Δ9-THC, and by extension cannabis, in humans.
Asunto(s)
Baclofeno/farmacología , Discriminación en Psicología/efectos de los fármacos , Dronabinol/farmacología , Agonistas del GABA/uso terapéutico , Alucinógenos/farmacología , Receptores de GABA-B/efectos de los fármacos , Adolescente , Adulto , Presión Sanguínea/efectos de los fármacos , Temperatura Corporal/efectos de los fármacos , Regulación de la Temperatura Corporal/efectos de los fármacos , Demografía , Interacciones Farmacológicas , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Masculino , Abuso de Marihuana/psicología , Desempeño Psicomotor/efectos de los fármacos , Factores Socioeconómicos , Trastornos Relacionados con Sustancias/psicología , Encuestas y Cuestionarios , Percepción del Tiempo/efectos de los fármacos , Adulto JovenRESUMEN
OBJECT: The authors evaluated the extent to which the Subdural Pharmacotherapy Device (SPD), chronically implanted over the frontal cortex to perform periodic, localized muscimol-delivery/CSF removal cycles, affects overall behavior, motor performance, electroencephalography (EEG) activity, and blood and CSF neurochemistry in macaque monkeys. METHODS: Two monkeys were used to adjust methodology and 4 monkeys were subjected to comprehensive testing. Prior to surgery, the animals' behavior in a large test chamber was monitored, and the motor skills required to remove food pellets from food ports located on the walls of the chamber were determined. The monkeys underwent implantation of the subdural and extracranial SPD units. The subdural unit, a silicone strip integrating EEG electrodes and fluid-exchange ports, was positioned over the right frontal cortex. The control unit included a battery-powered, microprocessor-regulated dual minipump and radiofrequency module secured to the cranium. After implantation, the SPD automatically performed periodic saline or muscimol (1.0 mM) deliveries at 12-hour intervals, alternating with local CSF removals at 6-hour intervals. The antiepileptic efficacy of this muscimol concentration was verified by demonstrating its ability to prevent focal acetylcholine-induced seizures. During SPD treatment, the monkeys' behavior and motor performance were again monitored, and the power spectrum of their radiofrequency-transmitted EEG recordings was analyzed. Serum and CSF muscimol levels were measured with high-performance liquid chromatography electrochemical detection, and CSF protein levels were measured with turbidimetry. RESULTS: The SPD was well tolerated in all monkeys for up to 11 months. The behavioral study revealed that during both saline and muscimol SPD treatment, the monkeys could achieve the maximum motor performance of 40 food-pellet removals per session, as before surgery. The EEG study showed that local EEG power spectra were not affected by muscimol treatment with SPD. The neurochemical study demonstrated that the administration of 1.0 mM muscimol into the neocortical subarachnoid space led to no detectable levels of this compound in the blood and cisternal CSF, as measured 1-125 minutes after delivery. Total protein levels were within the normal range in the cisternal CSF, but protein levels in the cortical-site CSF were significantly higher than normal: 361 ± 81.6 mg/dl. Abrupt discontinuation of 3-month, periodic, subdural muscimol treatments induced withdrawal seizures, which could be completely prevented by gradually tapering off the subdural muscimol concentration from 1.0 mM to 0.12-0.03 mM over a period of 2 weeks. The monkeys' general health and weight were maintained. Infection occurred only in one monkey 9 months after surgery. CONCLUSIONS: Long-term, periodic, transmeningeal muscimol delivery with the SPD is essentially a safe procedure. If further improved and successfully adapted for use in humans, the SPD can be used for the treatment of intractable focal neocortical epilepsy affecting approximately 150,000 patients in the US.
Asunto(s)
Anticonvulsivantes/administración & dosificación , Anticonvulsivantes/uso terapéutico , Conducta Animal/efectos de los fármacos , Agonistas del GABA/administración & dosificación , Agonistas del GABA/uso terapéutico , Muscimol/administración & dosificación , Muscimol/uso terapéutico , Animales , Anticonvulsivantes/efectos adversos , Peso Corporal/fisiología , Proteínas del Líquido Cefalorraquídeo/análisis , Cromatografía Líquida de Alta Presión , Convulsivantes , Implantes de Medicamentos , Electroencefalografía , Electrofisiología , Epilepsia del Lóbulo Frontal/tratamiento farmacológico , Lóbulo Frontal/cirugía , Agonistas del GABA/efectos adversos , Macaca radiata , Masculino , Muscimol/efectos adversos , Procedimientos Neuroquirúrgicos/métodos , Convulsiones/prevención & control , Programas Informáticos , Espacio Subdural/fisiología , Espacio Subdural/cirugía , Síndrome de Abstinencia a SustanciasRESUMEN
OBJECTIVE: To assess the effect of Ginkgo biloba and clonazepam, a γ-aminobutyric acid (GABA)-receptor agonist, upon tinnitus. METHODS: This was an open-label, randomised, crossover study. 27 men and 11 women (aged 16-80 (mean 58)) with tinnitus for more than 2 months were enrolled. Participants were randomised to either clonazepam or G biloba for the first 3 weeks. For the next 2 weeks of washout no medication was taken. For the final 3 weeks, subjects were given the other drug. The initial dose of clonazepam and G biloba was one tablet daily (clonazepam 0.5 mg; G biloba 40 mg). Subjects were instructed to increase the dose by one tablet every 3 days to a maximum of four tablets daily until they perceived a satisfactory decrease in tinnitus loudness or intolerable side effects. Tinnitus was assessed with pitch and loudness matching, tinnitus handicap inventory, and visual analogue scales of loudness, duration and annoyance. RESULTS: Comparing before and after each drug, clonazepam significantly improved tinnitus loudness (74% of subjects), duration (63%), annoyance (79%), and tinnitus handicap inventory score (61%), whereas the G biloba showed no significant differences on any of these measures. CONCLUSION: Clonazepam is effective in treating tinnitus; G biloba is ineffective.
Asunto(s)
Clonazepam/uso terapéutico , Agonistas del GABA/uso terapéutico , Ginkgo biloba , Fitoterapia/métodos , Extractos Vegetales/uso terapéutico , Acúfeno/tratamiento farmacológico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Estudios Cruzados , Femenino , Audición/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , Adulto JovenRESUMEN
Hot flushes are due to the lack of estrogens and are the most characteristic climacteric complaints. Hormone replacement therapy was the standard treatment but now its use is limited because of side effects. Need therefore arises to search for non-estrogenic alternatives. The molting hormone 20-beta-hydroxyecdysone (Ecd) is produced by several plants including spinach and has no estrogenic or androgenic properties but enhances GABAergic effects in neurons. Since GABAergic compounds can ameliorate hot flushes, we investigated the effects of Ecd on subcutaneous body temperature of intact and ovariectomized (ovx) rats. The subcutaneous body temperature was recorded at 5-min intervals over a period of 3 hours. Rats were then ovx, and skin temperatures were recorded after an acute intravenous (5 mg) and during subchronic and chronic oral application of Ecd (73 mg/animal/day). For additional control purposes, a group of ovx rats received food containing estradiol-17 ß (E2). Skin temperature in individual ovx animals fluctuated largely with peaks (hot flushes) occurring every 20-40 minutes. Following the i.v. treatment with Ecd, skin temperature dropped by more than 1 °C, an effect much larger than in the controls. One and two weeks later, hot flushes were only seen in ovx controls but not in intact, E2-, or Ecd-treated animals. As a consequence, E2 and Ecd intake significantly (p < 0.05) reduced the mean temperature in ovx rats during the various time points of the study. These results suggest that Ecd is efficient to prevent hot flushes in ovx rats.
Asunto(s)
Ecdisona/uso terapéutico , Agonistas del GABA/uso terapéutico , Sofocos/tratamiento farmacológico , Fitoterapia , Extractos Vegetales/uso terapéutico , Temperatura Cutánea/efectos de los fármacos , Spinacia oleracea/química , Animales , Ecdisona/administración & dosificación , Ecdisona/farmacología , Estradiol/farmacología , Femenino , Agonistas del GABA/administración & dosificación , Agonistas del GABA/farmacología , Ovariectomía , Extractos Vegetales/administración & dosificación , Extractos Vegetales/farmacología , Ratas , Ratas Sprague-DawleyRESUMEN
Baicalein (BA), one of the main flavonoids obtained from the Chinese medicinal herb Scutellaria baicalensis, usually exerts several pharmacological effects. In the central nervous system (CNS), BA exerts a protective effect on neurons against several neuronal insults among other effects, but it is not clear if this effect is due to its metabolite, baicalin. The purpose of the present study was to assess the anxiolytic-like and related properties of BA following its central administration (i.c.v.) in mice. BA (0.02, 0.2pmol) exerted an anxiolytic-like effect at low doses, increasing the time spent in open arms and the head-dipping whereas reducing the stretched-attend postures in the elevated plus-maze. BA also increased the duration of ether-induced sleep without affecting the pentylenetetrazol (PTZ)-induced convulsions. In addition, pretreatment with flumazenil (FMZ), PTZ, dehydroepiandrosterone sulfate (DHEAS), and dl-p-chlorophenilalanine ethyl ester (PCPA) were conducted in order to investigate its mechanism of action. PTZ and DHEAS, but not FMZ or PCPA, antagonized the BA's anxiolytic-like effect. Taken together our results showed that BA, when directly injected into the CNS, promotes anxiolytic-like and sedative effects, pharmacological activities dependent on GABAergic non-benzodiazepine sites but not on the 5-HT system.
Asunto(s)
Flavanonas/farmacología , Agonistas del GABA/farmacología , Agonistas del GABA/uso terapéutico , Antagonistas del GABA/farmacología , Convulsiones/tratamiento farmacológico , Sueño/efectos de los fármacos , Sueño/fisiología , Animales , Ansiolíticos/farmacología , Ansiolíticos/uso terapéutico , Sulfato de Deshidroepiandrosterona/farmacología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Éter/farmacología , Femenino , Fenclonina/análogos & derivados , Fenclonina/farmacología , Flavanonas/administración & dosificación , Flavanonas/antagonistas & inhibidores , Flavanonas/uso terapéutico , Flumazenil/farmacología , Inyecciones Intraventriculares , Aprendizaje por Laberinto/efectos de los fármacos , Aprendizaje por Laberinto/fisiología , Ratones , Pentilenotetrazol/farmacología , Convulsiones/inducido químicamenteRESUMEN
The effects of annomontine, a pyrimidine- ß-carboline alkaloid isolated from the root of ANNONA PURPUREA, on anxiety was studied in mice using the elevated plus-maze. The behavioral effects of this alkaloid on the pentobarbital-induced hypnosis, the locomotor activity in an open field, and the motor coordination in the rotarod test were also evaluated. The intraperitoneal injection of annomontine (1-30 mg/kg) increased in a dose-dependent way the number of visits to and the time spent in the open arms of the elevated plus-maze in comparison to the control animals. Such effects were blocked by the prior application of flumazenil (3 mg/kg; i. p.), a specific antagonist for the binding of benzodiazepines on the GABA (A) receptor. Under the same experimental conditions annomontine failed to affect the behavior of the animals in the pentobarbital-induced hypnosis test and had no effects on locomotion and motor coordination. These results suggest that annomontine possesses anxiolytic-like effects which may be mediated at the level of the benzodiazepine binding site on the GABA (A) receptor.
Asunto(s)
Annona/química , Ansiolíticos/farmacología , Ansiedad/tratamiento farmacológico , Conducta Animal/efectos de los fármacos , Carbolinas/farmacología , Agonistas del GABA/farmacología , Fitoterapia , Pirimidinas/farmacología , Animales , Ansiolíticos/aislamiento & purificación , Ansiolíticos/uso terapéutico , Benzodiazepinas/metabolismo , Sitios de Unión , Carbolinas/aislamiento & purificación , Carbolinas/uso terapéutico , Relación Dosis-Respuesta a Droga , Flumazenil/farmacología , Agonistas del GABA/aislamiento & purificación , Agonistas del GABA/uso terapéutico , Hipnosis , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Ratones , Ratones Endogámicos BALB C , Actividad Motora/efectos de los fármacos , Extractos Vegetales/química , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico , Raíces de Plantas , Pirimidinas/aislamiento & purificación , Pirimidinas/uso terapéuticoRESUMEN
BACKGROUND: Extensive research has focused on neuroprotection after spinal cord trauma to alleviate the effects of secondary injury. This study aims to investigate the neuroprotective effects of gabapentin in experimental spinal cord injury. METHODS: Thirty-six adult, male Wistar rats received spinal cord injury using the clip compression method. Animals were divided into five groups. High (200 mg/kg) and low doses (30 mg/kg) of gabapentin were administered to the animals in the treatment groups after spinal cord trauma and ultrastructural findings and lipid peroxidation levels of these two groups were compared with the animals that received only laminectomy, only trauma, and trauma and 30 mg/kg methylprednisolone. RESULTS: Regarding tissue lipid peroxidation levels after trauma, animals in gabapentin groups demonstrated better results than the trauma group. However, these results were no better than the methylprednisolone group. The results regarding the ultrastructural findings were similar. Treatment groups demonstrated better ultrastructural findings than the trauma group. In addition, the results of the high dose gabapentin group were significantly better than the low dose gabapentin group. CONCLUSIONS: Gabapentin demonstrated similar neuroprotective effects as methylprednisolone in early phase of spinal cord injury. Further studies with different experimental settings including neurological outcome are required to achieve conclusive results.
Asunto(s)
Aminas/farmacología , Ácidos Ciclohexanocarboxílicos/farmacología , Fármacos Neuroprotectores/farmacología , Traumatismos de la Médula Espinal/tratamiento farmacológico , Ácido gamma-Aminobutírico/farmacología , Aminas/uso terapéutico , Animales , Bloqueadores de los Canales de Calcio/farmacología , Bloqueadores de los Canales de Calcio/uso terapéutico , Canales de Calcio Tipo L/efectos de los fármacos , Canales de Calcio Tipo L/fisiología , Ácidos Ciclohexanocarboxílicos/uso terapéutico , Modelos Animales de Enfermedad , Antagonistas de Aminoácidos Excitadores/farmacología , Antagonistas de Aminoácidos Excitadores/uso terapéutico , Agonistas del GABA/farmacología , Agonistas del GABA/uso terapéutico , Gabapentina , Masculino , Fármacos Neuroprotectores/uso terapéutico , Distribución Aleatoria , Ratas , Ratas Wistar , Traumatismos de la Médula Espinal/patología , Traumatismos de la Médula Espinal/fisiopatología , Resultado del Tratamiento , Ácido gamma-Aminobutírico/uso terapéuticoAsunto(s)
Esfínter Esofágico Superior/efectos de los fármacos , Agonistas del GABA/uso terapéutico , Reflujo Gastroesofágico/tratamiento farmacológico , Relajación Muscular/efectos de los fármacos , Ácidos Fosfínicos/uso terapéutico , Propilaminas/uso terapéutico , Quimioterapia Combinada , Esfínter Esofágico Superior/fisiopatología , Reflujo Gastroesofágico/fisiopatología , Humanos , Presión , Inhibidores de la Bomba de Protones/uso terapéutico , Factores de Tiempo , Resultado del TratamientoRESUMEN
Defined pharmacologically by its insensitivity to the GABA(A) antagonist bicuculline and sensitivity to the GABA analogue baclofen, the G protein-linked gamma-aminobutyric acid type B (GABA(B)) receptor couples to adenylyl cyclase, voltage-gated calcium channels, and inwardly-rectifying potassium channels. On the basis of a wealth of preclinical data in conjunction with early clinical observations that baclofen improves symptoms of gastroesophageal reflux disease (GERD), the GABA(B) receptor has been proposed as a therapeutic target for a number of diseases including GERD. Subsequently, there has been a significant effort to develop a peripherally-restricted GABA(B) agonist that is devoid of the central nervous system side effects that are observed with baclofen. In this article we review the in vitro and in vivo pharmacology of the peripherally-restricted GABA(B) receptor agonists and the preclinical and clinical development of lesogaberan (AZD3355, (R)-(3-amino-2-fluoropropyl) phosphinic acid), a potent and predominately peripherally-restricted GABA(B) receptor agonist with a preclinical therapeutic window superior to baclofen.
Asunto(s)
Agonistas del GABA/uso terapéutico , Agonistas de Receptores GABA-B , Reflujo Gastroesofágico/tratamiento farmacológico , Animales , Evaluación Preclínica de Medicamentos , Agonistas del GABA/farmacología , Reflujo Gastroesofágico/metabolismo , Reflujo Gastroesofágico/fisiopatología , Humanos , Receptores de GABA-B/químicaRESUMEN
Potential mechanisms of Passiflora incarnata extracts and the effect of extraction methods on ingredients and biological effects were explored. Using the same batch of plant material, total flavonoid yields as measured by high-performance liquid chromatography coupled to diode array detection (HPLC-DAD) increased substantially with hot versus cold extraction methods. Whole Passiflora extract induced prominent, dose-dependent direct GABA(A) currents in hippocampal slices, but the expected modulation of synaptic GABA(A) currents was not seen. GABA was found to be a prominent ingredient of Passiflora extract, and GABA currents were absent when amino acids were removed from the extract. Five different extracts, prepared from a single batch of Passiflora incarnata, were administered to CF-1 mice for 1 week in their drinking water prior to evaluation of their behavioral effects. Anticonvulsant effects against PTZ-induced seizures were seen in mice that received 2 of the 5 Passiflora extracts. Instead of the anxiolytic effects described by others, anxiogenic effects in the elevated plus maze were seen in mice receiving any of the 5 Passiflora extracts.
Asunto(s)
Anticonvulsivantes/uso terapéutico , Ansiedad/tratamiento farmacológico , Agonistas del GABA/uso terapéutico , Hipocampo/efectos de los fármacos , Passiflora/química , Extractos Vegetales/uso terapéutico , Convulsiones/tratamiento farmacológico , Animales , Anticonvulsivantes/farmacología , Ansiedad/inducido químicamente , Relación Dosis-Respuesta a Droga , Flavonoides/efectos adversos , Flavonoides/farmacología , Flavonoides/uso terapéutico , Agonistas del GABA/farmacología , Hipocampo/fisiología , Masculino , Aprendizaje por Laberinto , Ratones , Ratones Endogámicos , Pentilenotetrazol , Fitoterapia , Extractos Vegetales/efectos adversos , Extractos Vegetales/farmacología , Ratas , Ratas Sprague-Dawley , Temperatura , Ácido gamma-Aminobutírico/farmacología , Ácido gamma-Aminobutírico/uso terapéuticoRESUMEN
This work investigates whether the two 1,5-benzodiazepine compounds: 4-(2-hydroxyphenyl)-1,5-benzodiazepin-2-one (RG0501) and Benzopyrano [4,3-c] 1,5-benzodiazepine (RG0502) have any neuropharmacological activities. Diazepam and Flunitrazepam were used as drug references. The investigational 1,5-BDZ were tested in vivo for potentiating hexobarbital-induced sleep and pentylenetetrazole (PTZ)-induced seizures. Our study demonstrated that the increase of sleep duration was significantly higher with RG0501 as compared to RG0502. However, RG0502 anticonvulsant effect was more pronounced than that of RG0501 in the range dose of 6.25-37.5 mg.kg(-1). From the 50 mg.kg(-1) dose, RG0502 offered a protection against clonic-tonic seizures as well as lethality (p< or =0.05). The results showed that the required doses to obtain a pharmacological activity were more than those of the references. This difference could be related to the lack of specific substituants responsible for the pharmacological activity in the tested compounds.
Asunto(s)
Anticonvulsivantes/uso terapéutico , Benzodiazepinas/uso terapéutico , Benzodiazepinonas/uso terapéutico , Benzopiranos/uso terapéutico , Epilepsia Tónico-Clónica/tratamiento farmacológico , Agonistas del GABA/uso terapéutico , Hipnóticos y Sedantes/uso terapéutico , Sueño/efectos de los fármacos , Animales , Anticonvulsivantes/química , Anticonvulsivantes/farmacología , Diazepam/farmacología , Diazepam/uso terapéutico , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Sinergismo Farmacológico , Epilepsia Tónico-Clónica/prevención & control , Flunitrazepam/farmacología , Flunitrazepam/uso terapéutico , Agonistas del GABA/química , Agonistas del GABA/farmacología , Hexobarbital/farmacología , Hipnóticos y Sedantes/química , Hipnóticos y Sedantes/farmacología , Masculino , Ratones , Estructura Molecular , Distribución Aleatoria , Receptores de GABA-A/efectos de los fármacos , Receptores de GABA-A/fisiologíaRESUMEN
The purpose of this study was to test the hypothesis that ischemia/reperfusion injury in the rat retina may be ameliorated by reducing retinal metabolism with either hypothermia or inhibitory GABA agonists. The intraocular pressure of each right eye in rats was raised to 130 mm Hg for 60 min with the left eye serving as normal control. The rats were divided into four groups in terms of drug and hypothermia treatment: (1) Untreated ischemia, (2) Hypothermia, (3) Baclofen/midazolam and (4) Baclofen/muscimol. Electroretinogram was recorded before ischemia and again after 10-day reperfusion. Histological analysis with H&E staining and cell counts was performed. Untreated ischemia/reperfusion resulted in severely reduced ERG responses. The ERG b-wave was reduced from 423+/-144 microV to 130+/-91 microV (mean+/-SD, n=5). With hypothermia the ERG b-wave was reduced from 499+/-80 microV to 237+/-111 microV (n=4). With combinations of baclofen and midazolam the ERG b-wave was reduced from 432+/-96 microV to 104+/-67 microV (n=7). In baclofen/muscimol treated eyes the ERG b-wave went from 426+/-101 microV to 148+/-118 microV (n=6). The histological tissue damage was severe in untreated ischemia and the baclofen/midazolam and baclofen/muscimol groups, but less severe in the hypothermia group. The GABA agonists do not provide any protection in our ischemia/reperfusion model. Our results are consistent with earlier reports that hypothermia may be helpful in ischemic conditions in the retina.